Cargando…

New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies

Photosensitizers (PSs) have shown great potentials as molecular contrast agents in photodynamic diagnosis (PDD) of cancer. While the diagnostic values of PSs have been proven previously, little efforts have been put into developing optical imaging and diagnostic algorithms. In this article, we revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivo, Malini, Fu, Chit Yaw, Raghavan, Vijaya, Lau, Weber Kam On
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281199/
https://www.ncbi.nlm.nih.gov/pubmed/22124793
http://dx.doi.org/10.1007/s10439-011-0462-7
_version_ 1782223933657841664
author Olivo, Malini
Fu, Chit Yaw
Raghavan, Vijaya
Lau, Weber Kam On
author_facet Olivo, Malini
Fu, Chit Yaw
Raghavan, Vijaya
Lau, Weber Kam On
author_sort Olivo, Malini
collection PubMed
description Photosensitizers (PSs) have shown great potentials as molecular contrast agents in photodynamic diagnosis (PDD) of cancer. While the diagnostic values of PSs have been proven previously, little efforts have been put into developing optical imaging and diagnostic algorithms. In this article, we review the recent development of optical probes that have been used in conjunction with a potent PS, hypericin (HY). Various fluorescence techniques such as laser confocal microscopy, fluorescence urine cytology, endoscopy and endomicroscopy are covered. We will also discuss about image processing and classification approaches employed for accurate PDD. We anticipate that continual efforts in these developments could lead to an objective PDD and complete surgical clearance of tumors. Recent advancements in nanotechnology have also opened new horizons for PSs. The use of biocompatible gold nanoparticles as carrier for enhanced targeted delivery of HY has been attained. In addition, plasmonic properties of nanoparticles were harnessed to induce localized hyperthermia and to manage the release of PS molecules, enabling a better therapeutic outcome of a combined photodynamic and photothermal therapy. Finally, we discuss how nanoparticles can be used as contrast agents for other optical techniques such as optical coherence tomography and surface-enhanced Raman scattering imaging.
format Online
Article
Text
id pubmed-3281199
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-32811992012-03-01 New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies Olivo, Malini Fu, Chit Yaw Raghavan, Vijaya Lau, Weber Kam On Ann Biomed Eng Article Photosensitizers (PSs) have shown great potentials as molecular contrast agents in photodynamic diagnosis (PDD) of cancer. While the diagnostic values of PSs have been proven previously, little efforts have been put into developing optical imaging and diagnostic algorithms. In this article, we review the recent development of optical probes that have been used in conjunction with a potent PS, hypericin (HY). Various fluorescence techniques such as laser confocal microscopy, fluorescence urine cytology, endoscopy and endomicroscopy are covered. We will also discuss about image processing and classification approaches employed for accurate PDD. We anticipate that continual efforts in these developments could lead to an objective PDD and complete surgical clearance of tumors. Recent advancements in nanotechnology have also opened new horizons for PSs. The use of biocompatible gold nanoparticles as carrier for enhanced targeted delivery of HY has been attained. In addition, plasmonic properties of nanoparticles were harnessed to induce localized hyperthermia and to manage the release of PS molecules, enabling a better therapeutic outcome of a combined photodynamic and photothermal therapy. Finally, we discuss how nanoparticles can be used as contrast agents for other optical techniques such as optical coherence tomography and surface-enhanced Raman scattering imaging. Springer US 2011-11-29 2012 /pmc/articles/PMC3281199/ /pubmed/22124793 http://dx.doi.org/10.1007/s10439-011-0462-7 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Olivo, Malini
Fu, Chit Yaw
Raghavan, Vijaya
Lau, Weber Kam On
New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies
title New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies
title_full New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies
title_fullStr New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies
title_full_unstemmed New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies
title_short New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies
title_sort new frontier in hypericin-mediated diagnosis of cancer with current optical technologies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281199/
https://www.ncbi.nlm.nih.gov/pubmed/22124793
http://dx.doi.org/10.1007/s10439-011-0462-7
work_keys_str_mv AT olivomalini newfrontierinhypericinmediateddiagnosisofcancerwithcurrentopticaltechnologies
AT fuchityaw newfrontierinhypericinmediateddiagnosisofcancerwithcurrentopticaltechnologies
AT raghavanvijaya newfrontierinhypericinmediateddiagnosisofcancerwithcurrentopticaltechnologies
AT lauweberkamon newfrontierinhypericinmediateddiagnosisofcancerwithcurrentopticaltechnologies